The DOI matches its Crossref record; 65 of the 68 references it cites were found in a registry or an index; 4 of the 39 sources its claims cite were checked for support.
Effect of a fermented milk containing Bifidobacterium animalis DN‐173 010 on the health‐related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double‐blind, controlled trial
Open accessAbstract
BACKGROUND: Health-related quality of life (HRQoL) has been rarely evaluated as a primary endpoint in the assessment of the effect of probiotics on the irritable bowel syndrome (IBS). AIM: To study the effects of fermented milk containing Bifidobacterium animalis DN-173 010 and yoghurt strains on the IBS in a multicentre, double-blind, controlled trial. METHODS: A total of 274 primary care adults with constipation-predominant IBS (Rome II) were randomized to consume for 6 weeks either the test fermented milk or a heat-treated yoghurt (control). HRQoL and digestive symptoms were assessed after 3 and 6 weeks on an intention-to-treat population of 267 subjects. RESULTS: The HRQoL discomfort score, the primary endpoint, improved (P < 0.001) in both groups at weeks 3 and 6. The responder rate for the HRQoL discomfort score was higher (65.2 vs. 47.7%, P < 0.005), as was the decrease in bloating score [0.56 +/- (s.d.)1.01 vs. 0.31 +/- 0.87, P = 0.03], at week 3 in the test vs. the control group. In those subjects with <3 stools/week, stool frequency increased (P < 0.001) over 6 weeks in the test vs. control group. CONCLUSIONS: This study suggests a beneficial effect of a probiotic food on discomfort HRQoL score and bloating in constipation-predominant IBS, and on stool frequency in subjects with <3 stools/week.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
22 Own result · 19 No full text of the sources · 8 Own method · 3 Partly supported · 3 Own interpretation · 2 Sources not found · 1 Supported · 1 Not checked yet · accuracy not yet measured
Every source the paper cites for this claim was checked and supports it.
In the paper
“The discomfort dimension of FDDQL, a validated questionnaire, 29 was able to capture the improvement in multiple IBS symptoms”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
What the sources say
- Supportedcites [29] 29. Chassany O, Marquis P, Scherrer B, et al. Validation of a specific quality of life questionnaire for functional diges- tive disorders. Gut 1999; 44: 527-533. source
Citation 29 immediately follows “a validated questionnaire,” so it supports the identification of the FDDQL as validated, not the subsequent claim about detecting improvement. The Discussion reports satisfactory psychometric properties, and Table 3 lists a discomfort scale. (LLM, conf=0.92)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In healthy adults as well as elderly subjects, a fermented milk containing Bifidobacterium animalis DN-173 010 alone or in association with the yoghurt starters Lactobacillus bulgaricus and Streptococcus thermophilus has been shown to decrease orofecal and ⁄ or colonic, especially sigmoid, transit time; [22][23][24][25]”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites [22] 22. Me ´ance S, Cayuela C, Turchet P, Raimondi A, Lucas C, Antoine JM. A fermented milk with a Bifidobacterium probiotic strain DN-173 010 shortened oro-fecal gut transit time in elderly. Microb Ecol Health Dis 2001; 13: 217- 222. source
- Not checked — no full text of the sourcecites [23] 23. Me ´ance S, Cayuela C, Turchet P, Rai- mondi A, Lucas C, Antoine JM. Recent advances in the use of functional foods: effects of the commercial fermented milk with Bifidobacterium animalis strain DN-173 010 and yoghurt strains on gut transit time in the elderly. Mic- rob Ecol Health Dis 2003; 15: 15-22. source
- Partly supportedcites [24] 24. Marteau P, Cuillerier E, Me ´ance S, et al. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: A double blind rand- omised controlled study. Aliment Phar- macol Ther 2002; 16: 587-593. sourceExperimental — accuracy not yet measured
The Discussion (p. 5) reports shorter total colonic and sigmoid transit times in healthy women who consumed fermented milk containing B. animalis DN-173 010 plus yoghurt cultures. This paper does not establish the claim for elderly subjects, orofecal transit time, or milk containing the strain without yoghurt cultures. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A clear-cut effect of probiotics on constipation per se has been quite rarely shown in IBS subjects, except in two studies.17,64”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [17] 17. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1581- 1590. source
- Partly supportedcites [64] 64. Koebnick C, Wagner I, Leitzmann P, Stern U, Zunft HJ. Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol 2003; 17: 655-659. sourceExperimental — accuracy not yet measured
The Results report improved constipation symptoms with the probiotic, and the Introduction says only a few studies had examined probiotics for constipation. But Patients and Methods describes participants with chronic idiopathic constipation, not an identified IBS population; the paper also does not establish that exactly two studies showed a clear-cut effect in IBS subjects. (LLM, conf=0.87)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The stress impact dimension was more (P < 0.05) improved, at week 6, in the control as compared to the test product group.”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > Health-related quality of life
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, we observed an increasing placebo effect in the control group from week 3 to week 6, which may account for the non-significant effect of test product on bloating and responder rate for discomfort dimension of FDDQL at week 6.”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The improvement in bloating score was significantly (P = 0.03) higher at week 3 in the test Changes from baseline”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > Bloating, abdominal pain and global digestive symptom assessment
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Score changes, at weeks 3 and 6 vs. baseline, of diet, sleep, health perception and coping with disease dimensions, and the global score did not differ significantly between groups (Table 3).”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > Health-related quality of life
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The effect size between groups at week 3 is 0.22 in favour of the test group.”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > Health-related quality of life
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The percentage of responders for the discomfort dimension was significantly higher (65.2 vs. 47.7%,P = 0.003) at week 3, in the test product as compared to the control group.”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > Health-related quality of life
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“A high ''placebo'' effect was observed in the control group in the present work, which confirms well-known data reported in IBS placebo-controlled trials showing an average placebo response rate of 40-45%.”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [45] 45. Enck P, Klosterhalfen S. The placebo response in functional bowel disorders: perspectives and putative mechanisms. Neurogastroenterol Motil 2005; 17: 325-331. source
- Not checked — no full text of the sourcecites [46] 46. Pitz M, Cheang M, Bernstein CN. Defi- ning the predictors of the placebo response in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 237-247. source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 19
- It may state two separate claims as one. 23
- The quote only partly states this claim. 3
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A similar alleviating effect on bloating of VSL#3, 55 a mixture of 8 probiotics, and of B. infantis 35624 16 has been reported in a study population of IBS subjects (35 and 77 subjects, respectively).”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
What the sources say
- Partly supportedcites [55] 55. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a pro- biotic, VSL#3, on gut transit and symp- toms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 895-904. sourceExperimental — accuracy not yet measured
The Discussion reports that VSL#3 appeared to reduce bloating in diarrhoea-predominant IBS, although the between-group difference was only borderline significant (Other symptom assessments; P = 0.09). The Demographic characteristics section says 25 patients were randomized, not 35. The separately cited B. infantis study and its 77 subjects are not attributed to this source. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [16] 16. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551. source
plaindirectn = 77- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The scores of daily activities and anxiety improved (P < 0.001) at weeks 3 and 6, as compared to baseline, in both groups; the improvement was significantly higher in the control vs. the test product group (Table 3).”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > Health-related quality of life
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, in spite of this, the test product exhibited a difference over the control group of 17.5% in the rate of responders for HRQoL discomfort score, which in turn results in a number needed to treat of 5.7.”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the ITT population (n = 267), stool frequency (Figure 2a) and consistency (data not shown) did not differ between the test product and control groups.”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > Stool characteristics
plainn = 267- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the present study, we observed a significant relief in abdominal bloating, for the whole probiotic subject group and for the subgroup characterized by a stool frequency of <3 stools ⁄ week.”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Ten subjects from the control group and 13 from the test product group reported minor adverse events throughout the study.Four subjects in the control group and three in the test group stopped the consumption of the product after an adverse event.Two subjects reported serious adverse events in the control group.”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > Adverse events
plainn = 10- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“HRQoL discomfort score and responder rate, bloating, abdominal pain and global digestive symptom scores improved (P < 0.05) at week 6 in the test product but not in the control subgroup.”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > Stool characteristics
plaindirectn = 19 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the subgroup (n = 19) of constipated IBS subjects, defined on the basis of <3 bowel movements per week, stool frequency increased (P < 0.001) over the 6-week period of product consumption, showing effect as soon as week 1, in the test product subgroup as compared to the control subgroup (Figure 2b).”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > Stool characteristics
plaindirectn = 19 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Discomfort dimension score, the primary HRQoL endpoint, improved (P < 0.001) at weeks 3 and 6, as compared to baseline, in both groups but the improvement did not significantly differ between groups (Table 2).”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > Health-related quality of life
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In conclusion, the present large-scale study strongly suggests a beneficial effect of a probiotic food containing B. animalis DN-173010 on HRQoL discomfort score and bloating, and also on stool frequency in those subjects with <3 stools per week.”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The increase in stool frequency, unaccompanied by a significant change in stool consistency scores, showed a rapid onset, i.e. after 1 week of product consumption, and was sustained throughout the 6-week study.”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one. The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In conclusion, the present large-scale study strongly suggests a beneficial effect of a probiotic food containing B. animalis DN-173010 on HRQoL discomfort score and bloating, and also on stool frequency in those subjects with <3 stools per week.”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“It is noteworthy that the favourable probiotic effects in this subgroup also included a significant alleviation of bloating and global digestive symptom score.”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In addition, analyses of HRQoL, IBS symptoms and stool characteristics data were performed in the subgroup of those definitely constipated subjects (n = 19), as defined on the only basis of <3 stools per week; a lower significance level (P < 0.001) was applied for judging results in this subgroup, as recommended.36”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > Statistical methods
What the sources say
- Not checked — no full text of the sourcecites [36] 36. Lagakos SW. The challenge of subgroup analyses : reporting without distorting. N Engl J Med 2006; 354: 1667-1669. source
plainn = 19- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The self-reported levels of product consumption were 96.3 Æ 9.3% and 96.7 Æ 6.1% in the test product and control groups, respectively.”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > Compliance to product consumption
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“From the 276 enrolled subjects, 274 were randomized.Seven subjects were subsequently excluded (premature withdrawal) leaving 135 subjects assigned to the test product group and 132 to the control group giving an ITT population of 267.”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > Subjects
plainn = 276- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“The significant reduction of bloating score we observed appears to be of special interest, as the magnitude of symptom reduction by standard medical care has been shown to be significantly greater in subjects with severe IBS as compared to subjects with moderate or mild IBS.44”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [44] 44. Withehead WE, Palsson OS, Levy RL, Feld AD, VonKorff M, Turner M. Reports of ''satisfactory relief'' by IBS patients receiving usual medical care are con- founded by baseline symptom severity and do not accurately reflect symptom improvement. Am J Gastroenterol 2006; 101: 1057-1065. source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“This was assessed by the self-administration of the FDDQL questionnaire as developed and validated by Chassany et al., 29”
- Also stated in: § DISCUSSION · plain
“The discomfort dimension of FDDQL, a validated questionnaire, 29”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > Health-related quality of life
What the sources say
- Not matchedcites Chassany et al., 29
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Also stated in: § DISCUSSION · plain
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“To achieve a number of 114 subjects per group, 138 subjects per group were finally recruited to take into account premature withdrawals and missing values for main criteria.”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > Statistical methods
plainn = 138- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All analyses were done on the intention-to-treat (ITT) population corresponding to subjects having consumed at least one pot of product.”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > Statistical methods
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The primary endpoint as prespecified in the protocol was the discomfort HRQoL dimension that measures the problem impact of the whole IBS symptoms on HRQoL at week 3.”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > Health-related quality of life
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“To the best of our knowledge, only two studies 16,17 reporting the effects of probiotics in IBS have used a specific IBS HRQoL questionnaire: this is in line with the limited number of subjects in most of the previously published trials on the probiotics-IBS topic.”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [16] 16. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551. source
- Not checked — no full text of the sourcecites [17] 17. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1581- 1590. source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“A Cochrane systematic review of antispasmodic agents in IBS yielded a number needed to treat of 6. 52”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [52] 52. Quartero AO, Meineche-Schmidt V, Muris J, Rubin G, de Wit N. Bulking agents, antispasmodic and antidepres- sant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005; 2: CD003460. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Although IBS is not a lifethreatening disease, health-related quality of life (HRQoL) is impaired.[10][11][12][13]”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites [10] 10. Amouretti M, Le Pen C, Gaudin AF, et al. Impact of irritable bowel syn- drome (IBS) on health-related quality of life (HRQOL). Gastroenterol Clin Biol 2006; 30: 241-246. source
- Not checked — no full text of the sourcecites [11] 11. ten Berg MJ, Goettsch WG, van den BG, Smout AJ, Herings RM. Quality of life of patients with irritable bowel syn- drome is low compared to others with chronic diseases. Eur J Gastroenterol Hepatol 2006; 18: 475-481. source
- Not checked — no full text of the sourcecites [12] 12. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-rela- ted quality of life. Gastroenterology 2000; 119: 654-660. source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“HRQoL goes beyond symptoms and functional status and thus measures broader concepts; therefore it is quite logical that the expected improvement over time and the expected differences between groups of the HRQoL endpoint are smaller than the ones expected for symptoms.39”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [39] 39. Corazziari E, Bytzer P, Delvaux M, et al. Clinical trial guidelines for pharmacolo- gical treatment of irritable bowel syn- drome. Aliment Pharmacol Ther 2003; 18: 569-580. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Some probiotic strains, either single (Bifidobacterium Infantis 36524, Lactobacillus Plantarum 299v) or combined (VSL#3), have been associated with a significant alleviation of IBS symptoms, [14][15][16][17] while others proved ineffective.[18][19][20]”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites [14] 14. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 1231-1238. source
- Not checked — no full text of the sourcecites [15] 15. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005; 17: 687-696. source
- Not checked — no full text of the sourcecites [16] 16. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551. source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Indeed, one study with alosetron has reported a significant improvement of HRQoL, clearly showing the sensitivity of HRQoL instruments to detect positive effects in trials.43”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [43] 43. Watson ME, Lacey L, Kong S, et al. Alosetron improves quality of life in women with diarrhoea-predominant irritable bowel syndrome. Am J Gast- roenterol 2001; 96: 455-459. source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Bloating, a supportive symptom of IBS diagnosis and a functional bowel disorder per se in the Rome II 7 and the very recent Rome III classifications, 8 is the most common abdominal complaint in IBS subjects, being reported and considered as the most bothersome symptom by 96% and 60% of them respectively. 9”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites [9] 9. Azpiroz F, Malagelada JR. Abdominal bloating. Gastroenterology 2005; 129: 1060-1078. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“B. animalis DN-173 010 survives complete transit through the digestive tract and is recovered live in stools in large quantities relative to the quantity initially ingested.[26][27][28]”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites [26] 26. Berrada N, Lemeland JF, Laroche G, Thouvenot P, Piaia M. Bifidobacterium from fermented milks: Survival during gastric transit. J Dairy Sci 1991; 74: 409-413. source
- Not checked — no full text of the sourcecites [27] 27. Pochart P, Marteau P, Bouhnik Y, God- erel I, Bourlioux P, Rambaud JC. Survi- val of Bifidobacteria ingested via fermented milk during their passage through the human small intestine: an in vivo study using intestinal perfusion. Am J Clin Nutr 1992; 55: 78-80. source
- Not checked — no full text of the sourcecites [28] 28. Duez H, Pelletier C, Cools S, et al. A colony-immunobloting method for quantitative detection of a Bifidobacte- rium animalis probiotic strain in human faeces. J Appl Microbiol 2000; 88: 1019-1027. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“although subjects with mild symptoms are the most likely to report satisfactory relief, they showed, in a recent study, no average decrease in symptom severity or improvement in IBS-QoL, while, conversely, subjects with severe-symptoms had the largest reductions in IBS symptom severity and the largest improvements in IBS-QoL but were the least likely to report satisfactory relief.44”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [44] 44. Withehead WE, Palsson OS, Levy RL, Feld AD, VonKorff M, Turner M. Reports of ''satisfactory relief'' by IBS patients receiving usual medical care are con- founded by baseline symptom severity and do not accurately reflect symptom improvement. Am J Gastroenterol 2006; 101: 1057-1065. source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“After a pilot study in a total of 80 male ⁄ female IBS subjects, 16 B. infantis 36524 proved capable in a large-scale trial on 362 (90 per group) primary care female subjects 17 to alleviate major symptoms of IBS, a clinical effect associated with an anti-inflammatory one as suggested by the correction of an abnormal interleukin (IL) 10 ⁄ IL12 blood ratio.16”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites [16] 16. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551. source
- Not checked — no full text of the sourcecites [17] 17. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1581- 1590. source
plaindirectn = 362- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“The alleviating effect of the latter probiotic has been very recently confirmed and extended, in a large randomized controlled trial.17”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [17] 17. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1581- 1590. source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
In the paper
“a probiotic which previously showed no effect on stool frequency in a more limited number of subjects.16”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [16] 16. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Consistent with our observation is the previous finding that the probiotics tested in the present study may accelerate the intestinal, especially colonic and sigmoid, speed of transit.[22][23][24][25]”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
What the sources say
- Not matchedcites [22][23][24][25]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“even though the sample size was not calculated for the multiple comparisons done”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The most important one 17 concerned 362 primary care subjects with any bowel habit subtype having received for 4 weeks B. infantis 35624”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [17] 17. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1581- 1590. source
plainn = 362- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“One study in patients with IBS-C36 reported no significant difference between the probiotic and placebo groups for the change from baseline in the discomfort dimension score of the Functional Digestive Disorders Quality of Life (FDDQL) questionnaire (primary end point); however, the probiotic group had a significantly greater proportion of responders for the discomfort dimension score than the”
From Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide (2013) · cites this paper as [36]
In the citing paper
“and another study of the same probiotic reported a significant improvement from baseline in the probiotic group, but not in the placebo group, in a subanalysis of patients with fewer than three bowel movements/week.36”
From Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide (2013) · cites this paper as [36]
In the citing paper
“Twelve studies evaluated abdominal pain as a secondary end point only. Results from these studies were mixed: one reported a negative effect of the specific probiotic treatment,59 eight (examining six different probiotics) reported no significant effect28–38 and three reported a significant beneficial effect of three different probiotics35,39”
From Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide (2013) · cites this paper as [36]
In the citing paper
“all three studies that examined flatus as a primary end point,30,57 and four of seven studies in which flatus was a secondary end point only,28–38 showed no significant difference between seven specific probiotic treatments and control.”
From Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide (2013) · cites this paper as [36]
In the citing paper
“Two studies reported no difference between specific probiotic treatments and placebo,28–37 and one study reported a significant worsening of diarrhoea with the specific probiotic treatment compared with placebo.59”
From Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide (2013) · cites this paper as [36]
In the citing paper
“Two studies evaluated overall IBS symptoms as a secondary end point only, and both reported a significant beneficial effect of the specific probiotic treatments33–39”
From Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - an evidence-based international guide (2013) · cites this paper as [36]
In the citing paper
“Efficacy of probiotic administration for symptoms of bloating have been less consistently reported153 although some studies in IBS patients have suggested benefit with specific probiotic strains including B. lactis DN-173118, Bifidobacterium animalis DN-173 010154, and VSL#3155.”
From The gut Microbiome in adult and pediatric functional gastrointestinal disorders (2019) · cites this paper as [154]
In the citing paper
“Several other clinical trials have investigated the effect of either probiotic strain(s) alone, i.e.Propionibacterium (34) and VSL#3 (35) or FM (36,37) and have failed to demonstrate a positive effect on transit time.”
In the citing paper
“These findings are supported by a multicenter, randomized, double-blind, controlled trial using Bifidobacterium animalis, strain DN-173 010. This trial reported an improved health-related quality of life score in patients with constipation-predominant IBS.32”
From Probiotics and the gut microbiota in intestinal health and disease (2010) · cites this paper as [32]
In the citing paper
“Other smaller studies reported some beneficial effects with other probiotic strains including Bifidobacterium animalis DN-173 010 (74), Bifidobacterium bifidum MIMBb75 (72), Lactobacillus plantarum 299V (117), Saccharomyces boulardii (37), and combination of Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 (144) and multispecies probiotic mixtures (71, 87, 88).”
From Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome (2013) · cites this paper as [74]
In the citing paper
“Two randomized studies using products containing Bifidobacterium lactis DN-173 010 showed a significant increase in the frequency of evacuation when compared to the control group [13,14].”
In the citing paper
“A study by Guyonet and co-workers [14] showed an improvement in bowel function in constipated subjects with Irritable Bowel Syndrome after the use of the same B. lactis for six weeks.”
In the citing paper
“This large scale (267 IBS constipation predominant, Rome II criteria), double-blind, randomized, controlled, parallel group study over 6 wk demonstrated that daily consumption of this product alleviates bloating and improves digestive comfort as assessed by the Functional Digestive Disorders Quality of Life questionnaire.”
From Effect of a fermented milk containing Bifidobacterium lactis DN-173010 on Chinese constipated women (2008) · cites this paper as [18]
In the citing paper
“An increase in stool frequency was also observed in subjects with the lowest stool frequency (< 3 or 4 bowel movements/wk) without any change of stool consistency.”
From Effect of a fermented milk containing Bifidobacterium lactis DN-173010 on Chinese constipated women (2008) · cites this paper as [18]
In the citing paper
“Specific probiotics help relieve overall symptom burden in some patients with IBS High [147,149,150,152,156-157,169, 174,176-178]”
From Gut microbiota role in irritable bowel syndrome: New therapeutic strategies (2016) · cites this paper as [157]
In the citing paper
“Specific probiotics help relieve overall symptom burden in some patients with C-IBS Low [147,156-157]”
From Gut microbiota role in irritable bowel syndrome: New therapeutic strategies (2016) · cites this paper as [157]
In the citing paper
“In addition, probiotic intervention trials showed that Bifidobacterium strains reduced bloating in irritable bowel syndrome.”
From Adaptation to tolerate high doses of arabinoxylan is associated with fecal levels of Bifidobacterium longum (2024) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > INTRODUCTION
“B. infantis 36524 proved capable in a large-scale trial on 362 (90 per group) primary care female subjects 17”
§ Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and > References
“17. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.”
Citations
Cites
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Stool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
Effect Sizes for Interpreting Changes in Health Status
Kazis, L. E., Anderson, J. J., & Meenan, R. F. (1989) · Medical Care · doi:10.1097/00005650-198903001-00015 · Cited by 2,401
Determining a minimal important change in a disease-specific quality of life questionnaire
JUNIPER, E. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90036-1 · Cited by 1,824
O’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O’Sullivan, G. C., Kiely, B., Collins, J. K., Shanahan, F., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.050 · Cited by 1,448
AGA technical review on irritable bowel syndrome.
Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37095 · Cited by 1,384
Whorwell, P. J., Altringer, L., Morel, J., Bond, Y., Charbonneau, D., O'Mahony, L., Kiely, B., Shanahan, F., & Quigley, E. M. M. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00734.x · Cited by 799
The impact of irritable bowel syndrome on health-related quality of life
Gralnek, I. M., Hays, R. D., Kilbourne, A., Naliboff, B., & Mayer, E. A. (2000) · Gastroenterology · doi:10.1053/gast.2000.16484 · Cited by 781
Pimentel, M., Chow, E. J., & Lin, H. C. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07234.x · Cited by 670
Research works printed but not linked: 2
- FDA Guidance for Industry, 2006, Patient‐reported outcome measures: use in medical product development to support labelling claims
- European Agency for the Evaluation of Medicinal Products (EMEA), 2006, Committee for proprietary medicinal products (CPMP). Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome
Cited by
Sorted by citations
The pros, cons, and many unknowns of probiotics
Suez, J., Zmora, N., Segal, E., & Elinav, E. (2019) · Nature Medicine · doi:10.1038/s41591-019-0439-x · Cited by 1,398
Bifidobacteria and Their Role as Members of the Human Gut Microbiota
O’Callaghan, A. A., & van Sinderen, D. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00925 · Cited by 1,160
Intestinal microbiota in functional bowel disorders: a Rome foundation report
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013) · Gut · doi:10.1136/gutjnl-2012-302167 · Cited by 939
Probiotics and the gut microbiota in intestinal health and disease
Gareau, M. G., Sherman, P. M., & Walker, W. A. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.117 · Cited by 907
Actinobacteria: A relevant minority for the maintenance of gut homeostasis
Binda, C., Lopetuso, L. R., Rizzatti, G., Gibiino, G., Cennamo, V., & Gasbarrini, A. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.02.012 · Cited by 828
Ford, A. C., Quigley, E. M. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E. E., Spiegel, B. M. R., & Moayyedi, P. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.202 · Cited by 747
The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review
Moayyedi, P., Ford, A. C., Talley, N. J., Cremonini, F., Foxx-Orenstein, A. E., Brandt, L. J., & Quigley, E. M. M. (2010) · Gut · doi:10.1136/gut.2008.167270 · Cited by 728
Ford, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E., Spiegel, B. M. R., & Quigley, E. M. M. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.187 · Cited by 664
Ford, A. C., Harris, L. A., Lacy, B. E., Quigley, E. M. M., & Moayyedi, P. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15001 · Cited by 619
SILK, D. B. A., DAVIS, A., VULEVIC, J., TZORTZIS, G., & GIBSON, G. R. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03911.x · Cited by 551
Intestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis
Tojo, R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i41.15163 · Cited by 533
Bifidobacteria and Their Health-Promoting Effects
Hidalgo-Cantabrana, C., Delgado, S., Ruiz, L., Ruas-Madiedo, P., Sánchez, B., & Margolles, A. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.bad-0010-2016 · Cited by 490
American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome
Ford, A. C., Moayyedi, P., Chey, W. D., Harris, L. A., Lacy, B. E., Saito, Y. A., & Quigley, E. M. M. (2018) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0084-x · Cited by 388
KAJANDER, K., MYLLYLUOMA, E., RAJILIĆ‐STOJANOVIĆ, M., KYRÖNPALO, S., RASMUSSEN, M., JÄRVENPÄÄ, S., ZOETENDAL, E. G., DE VOS, W. M., VAPAATALO, H., & KORPELA, R. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03542.x · Cited by 367
The Utility of Probiotics in the Treatment of Irritable Bowel Syndrome: A Systematic Review
Brenner, D. M., Moeller, M. J., Chey, W. D., & Schoenfeld, P. S. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.25 · Cited by 362
McKenzie, Y. A., Bowyer, R. K., Leach, H., Gulia, P., Horobin, J., O'Sullivan, N.-A., Pettitt, C., Reeves, L., Seamark, L., Williams, M., et al. (2016) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.12385 · Cited by 374
Chong, P. P., Chin, V. K., Looi, C. Y., Wong, W. F., Madhavan, P., & Yong, P. V. C. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01136 · Cited by 353
Gut microbiota role in irritable bowel syndrome: New therapeutic strategies
Distrutti, E., Monaldi, L., Ricci, P., & Fiorucci, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i7.2219 · Cited by 320
AGRAWAL, A., HOUGHTON, L. A., MORRIS, J., REILLY, B., GUYONNET, D., GOUPIL FEUILLERAT, N., SCHLUMBERGER, A., JAKOB, S., & WHORWELL, P. J. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03853.x · Cited by 334
Self-citationThe role of intestinal microbiota and the immune system.
Purchiaroni, F., Tortora, A., Gabrielli, M., Bertucci, F., Gigante, G. E., Ianiro, G., Ojetti, V., Scarpellini, E., & Gasbarrini, A. (2013) · PubMed · Cited by 297
A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome
Hoveyda, N., Heneghan, C., Mahtani, K. R., Perera, R., Roberts, N., & Glasziou, P. (2009) · BMC Gastroenterology · doi:10.1186/1471-230x-9-15 · Cited by 297
Guglielmetti, S., Mora, D., Gschwender, M., & Popp, K. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04633.x · Cited by 287
Engevik, M. A., Luk, B., Chang‐Graham, A. L., Hall, A., Herrmann, B. I., Ruan, W. H., Endres, B. T., Shi, Z., Garey, K. W., Hyser, J. M., et al. (2019) · mBio · doi:10.1128/mbio.01087-19 · Cited by 280
Probiotic Delivery through Fermentation: Dairy vs. Non-Dairy Beverages
Ranadheera, C. S., Vidanarachchi, J. K., Rocha, R. S., da Cruz, A. G., & Ajlouni, S. (2017) · Fermentation · doi:10.3390/fermentation3040067 · Cited by 281
Probiotics and health: An evidence-based review
Aureli, P., Capurso, L., Castellazzi, A. M., Clerici, M., Giovannini, M., Morelli, L., Poli, A., Pregliasco, F. E., Salvini, F. M., & Zuccotti, G. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.02.006 · Cited by 289
Genomic Insights into Bifidobacteria
Lee, J.-H., & O’Sullivan, D. J. (2010) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00004-10 · Cited by 293
Therapeutical use of probiotic formulations in clinical practice
Iannitti, T., & Palmieri, B. (2010) · Clinical Nutrition · doi:10.1016/j.clnu.2010.05.004 · Cited by 270
Communication between gastrointestinal bacteria and the nervous system
Bravo, J. A., Julio-Pieper, M., Forsythe, P., Kunze, W., Dinan, T. G., Bienenstock, J., & Cryan, J. F. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.09.010 · Cited by 261
Irritable Bowel Syndrome, Gut Microbiota and Probiotics
Lee, B. J., & Bak, Y. (2011) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2011.17.3.252 · Cited by 229
Layer, P., Andresen, V., Pehl, C., Allescher, H. ‐., Bischoff, S., Claßen, M., Enck, P., Frieling, T., Haag, S., Holtmann, G., et al. (2011) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0029-1245976 · Cited by 236
Bennet, S. M. P., Böhn, L., Störsrud, S., Liljebo, T., Collin, L., Lindfors, P., Törnblom, H., Öhman, L., & Simrén, M. (2018) · Gut · doi:10.1136/gutjnl-2016-313128 · Cited by 225
An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome
Brandt, L. J., Chey, W. D., Foxx-Orenstein, A. E., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P. S., Spiegel, B. M., Talley, N. J., & Moayyedi, P. (2009) · American Journal of Gastroenterology · doi:10.14309/00000434-200901001-00002 · Cited by 225
Hungin, A. P. S., Mulligan, C., Pot, B., Whorwell, P., Agréus, L., Fracasso, P., Lionis, C., Mendive, J., Philippart de Foy, J.-M., Rubin, G., et al. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12460 · Cited by 212
Clarke, G. A., Cryan, J. F., Dinan, T. G., & Quigley, E. M. M. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04965.x · Cited by 221
Recommendations for Probiotic Use—2011 Update
Floch, M. H., Walker, W. A., Madsen, K. L., Sanders, M. E., Macfarlane, G. T., Flint, H. J., Dieleman, L. A., Ringel, Y., Guandalini, S., Kelly, C. P., et al. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318230928b · Cited by 208
Pala, V. M., Sieri, S., Berrino, F., Vineis, P., Sacerdote, C., Palli, D., Masala, G., Panico, S., Mattiello, A., Tumino, R., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26193 · Cited by 195
Review article: probiotics and prebiotics in irritable bowel syndrome
SPILLER, R. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03750.x · Cited by 190
ZENG, J., LI, Y. ‐., ZUO, X. ‐., ZHEN, Y. ‐., YANG, J., & LIU, C. ‐. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03818.x · Cited by 189
Application of probiotics in food products—challenges and new approaches
Janković, I., Sybesma, W., Phothirath, P., Ananta, E., & Mercenier, A. (2010) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2010.03.009 · Cited by 171
Ponziani, F. R., Zocco, M. A., D’Aversa, F., Pompili, M., & Gasbarrini, A. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i25.4491 · Cited by 177
SIMRÉN, M., ÖHMAN, L., OLSSON, J., SVENSSON, U., OHLSON, K., POSSERUD, I., & STRID, H. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04183.x · Cited by 169
Parkes, G. C., Brostoff, J., Whelan, K., & Sanderson, J. D. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01869.x · Cited by 167
The gut Microbiome in adult and pediatric functional gastrointestinal disorders
Shin, A., Preidis, G. A., Shulman, R., & Kashyap, P. C. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.08.054 · Cited by 163
Aguilera, M., Cerdà-Cuéllar, M., & Martínez, V (2015) · Gut Microbes · doi:10.4161/19490976.2014.990790 · Cited by 162
Hungin, A. P. S., Mitchell, C. R., Whorwell, P., Mulligan, C., Cole, O., Agréus, L., Fracasso, P., Lionis, C., Mendive, J., Philippart de Foy, J. ‐., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14539 · Cited by 154
WILLIAMS, E. A., STIMPSON, J., WANG, D., PLUMMER, S., GARAIOVA, I., BARKER, M. E., & CORFE, B. M. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03848.x · Cited by 156
Efficacy of Probiotics in Irritable Bowel Syndrome: A Meta-Analysis of Randomized, Controlled Trials
Nikfar, S., Rahimi, R., Rahimi, F., Derakhshani, S., & Abdollahi, M. (2008) · Diseases of the Colon & Rectum · doi:10.1007/s10350-008-9335-z · Cited by 155
Effect of a fermented milk containing Bifidobacterium lactis DN-173010 on Chinese constipated women
Yang, Y.-X., He, M., Hu, G., Wei, J., Pages, P., Yang, X.-H., & Bourdu-Naturel, S. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.6237 · Cited by 151
Gut Microbiota as Potential Orchestrators of Irritable Bowel Syndrome
Bennet, S., Öhman, L., & Simrén, M. (2015) · Gut and Liver · doi:10.5009/gnl14344 · Cited by 144
Gut inflammation in chronic fatigue syndrome
Lakhan, S. E., & Kirchgessner, A. (2010) · Nutrition & Metabolism · doi:10.1186/1743-7075-7-79 · Cited by 143
Recommendations for Probiotic Use—2008
Floch, M. H., Walker, W. A., Guandalini, S., Hibberd, P. L., Gorbach, S. L., Surawicz, C. M., Sanders, M. E., García–Tsao, G., Quigley, E. M. M., Isolauri, E., et al. (2008) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31816b903f · Cited by 139
Sisson, G., Ayis, S., Sherwood, R. A., & Bjarnason, I. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12787 · Cited by 147
Prasanna, P. H. P., Grandison, A. S., & Charalampopoulos, D. (2014) · Food Research International · doi:10.1016/j.foodres.2013.11.013 · Cited by 135
McKenzie, Y. A., Alder, A., Anderson, W., Wills, A., Goddard, L., Gulia, P., Jankovich, E., Mutch, P., Reeves, L., Singer, A., et al. (2012) · Journal of Human Nutrition and Dietetics · doi:10.1111/j.1365-277x.2012.01242.x · Cited by 130
Chao, L., Liu, C., Sutthawongwadee, S., Li, Y., Lv, W., Chen, W., Yu, L., Zhou, J., Guo, A., Li, Z., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00421 · Cited by 125
AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders
Preidis, G. A., Weizman, A. V., Kashyap, P., & Morgan, R. L. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.060 · Cited by 137
Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis
Zhang, T., Zhang, C., Zhang, J., Sun, F., & Duan, L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.859967 · Cited by 125
Martins, F. S., Silva, A. A., Vieira, A. T., et al. (2009) · Archives of Microbiology · doi:10.1007/s00203-009-0491-x · Cited by 123
Enck, P., Zimmermann, K., Menke, G., Müller-Lissner, S. A., Martens, U., & Klosterhalfen, S. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01156.x · Cited by 124
Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate
Gallo, A., Passaro, G., Gasbarrini, A., Landolfi, R., & Montalto, M. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i32.7186 · Cited by 122
Korterink, J. J., Ockeloen, L., Benninga, M. A., Tabbers, M. M., Hilbink, M., & Deckers‐Kocken, J. M. (2014) · Acta Paediatrica · doi:10.1111/apa.12513 · Cited by 115
Recommendations for Probiotic Use—2015 Update: Proceedings and Consensus Opinion
Floch, M. H., Walker, W. A., Sanders, M. E., Nieuwdorp, M., Kim, A. S., Brenner, D. A., Qamar, A. A., Miloh, T. A., Guarino, A., Guslandi, M., et al. (2015) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000420 · Cited by 119
Nielsen, E. S., Garnås, E., Jensen, K. J., Hansen, L. H., Olsen, P. S., Ritz, C., Krych, L., & Nielsen, D. S. (2018) · Food & Function · doi:10.1039/c8fo00968f · Cited by 113
Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome
Ringel, Y., & Maharshak, N. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00207.2012 · Cited by 115
Majeed, M. A., Nagabhushanam, K., Natarajan, S., Sivakumar, A., Ali, F. H. M., Pande, A., Majeed, S., & Karri, S. K. (2015) · Nutrition Journal · doi:10.1186/s12937-016-0140-6 · Cited by 110
Sun, Z., Zhang, W., Guo, C., Yang, X., Liu, W., Wu, Y., Song, Y., Kwok, L. Y., Cui, Y., Menghe, B., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117912 · Cited by 97
Magro, D. O., de Oliveira, L. M. R., Bernasconi, I., de Souza Ruela, M., Credidio, L., Barcelos, I. K., Leal, R. F., Ayrizono, M. D. L. S., Fagundes, J. J., Teixeira, L. D. B., et al. (2014) · Nutrition Journal · doi:10.1186/1475-2891-13-75 · Cited by 105
Wang, H., Gong, J., Wang, W., Long, Y., Fu, X., Fu, Y., Qian, W., & Hou, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090153 · Cited by 108
Haller, D., Antoine, J., Bengmark, S., Enck, P., Rijkers, G. T., & Lenoir‐Wijnkoop, I. (2010) · Journal of Nutrition · doi:10.3945/jn.109.113746 · Cited by 106
Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis
Ortiz-Lucas, M., Aurelio, T., Saz, P., & Sebastián, J. J. (2013) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082013000100005 · Cited by 103
Agostini, S., Goubern, M., Tondereau, V., Salvador–Cartier, C., Bézirard, V., Lévèque, M., Keränen, H., Théodorou, V., Bourdu-Naturel, S., Goupil-Feuillerat, N., et al. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2011.01865.x · Cited by 106
Ligaarden, S. C., Axelsson, L., Naterstad, K., Lydersen, S., & Farup, P. G. (2010) · BMC Gastroenterology · doi:10.1186/1471-230x-10-16 · Cited by 103
Costa, R. L., Moreira, J., Lorenzo, A., & Lamas, C. C. (2018) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-018-2394-3 · Cited by 105
Probiotics and health: a review of the evidence
Weichselbaum, E. (2009) · Nutrition Bulletin · doi:10.1111/j.1467-3010.2009.01782.x · Cited by 100
Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
Li, B., Li, L., Deng, H., Guo, J., Shu, H., & Zhang, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00332 · Cited by 96
Guyonnet, D., Schlumberger, A., Mhamdi, L., Jakob, S., & Chassany, O. (2009) · British Journal of Nutrition · doi:10.1017/s0007114509990882 · Cited by 95
Self-citationMicrobiome and metabolome data integration provides insight into health and disease
Shaffer, M., Armstrong, A. J. S., Phelan, V. V., Reisdorph, N. A., & Lozupone, C. (2017) · Translational research · doi:10.1016/j.trsl.2017.07.001 · Cited by 86
Tabbers, M. M., Chmielewska, A., Roseboom, M. G., Crastes, N., Perrin, C., Reitsma, J. B., Norbruis, O., Szajewska, H., & Benninga, M. A. (2011) · Pediatrics · doi:10.1542/peds.2010-2590 · Cited by 93
McFarland, L. V., Karakan, T., & Karataş, A. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101154 · Cited by 101
Roberts, L. M., McCahon, D., HOLDER, R. L., Wilson, S., & Hobbs, R. F. (2013) · BMC Gastroenterology · doi:10.1186/1471-230x-13-45 · Cited by 87
The enteric microbiota in the pathogenesis and management of constipation
Quigley, E. M. M. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.01.003 · Cited by 87
Søndergaard, B., Olsson, J., Ohlson, K., Svensson, U., Bytzer, P., & Ekesbo, R. (2011) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2011.565066 · Cited by 84
Asha, M. Z., & Khalil, S. F. H. (2020) · Sultan Qaboos University medical journal · doi:10.18295/squmj.2020.20.01.003 · Cited by 85
McKenzie, Y. A., Thompson, J., Gulia, P., & Lomer, M. C. E. (2016) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.12386 · Cited by 91
Niu, H.-L., & Xiao, J. (2020) · International Journal of Surgery · doi:10.1016/j.ijsu.2020.01.142 · Cited by 90
Recent progress in the use of functional foods for older adults: A narrative review
Jędrusek‐Golińska, A., Górecka, D., Buchowski, M. S., Wieczorowska–Tobis, K., Gramza‐Michałowska, A., & Szymandera-Buszka, K. E. (2020) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12530 · Cited by 89
Eskandarzadeh, S., Effatpanah, M., Khosravi‐Darani, K., Askari, R., Hosseini, A. F., Reisian, M., & Jazayeri, S. (2019) · Nutritional Neuroscience · doi:10.1080/1028415x.2019.1598669 · Cited by 83
Efficacy of probiotics on anxiety-A meta-analysis of randomized controlled trials
Liu, B., He, Y., Wang, M., Liu, J., Ju, Y., Zhang, Y., Liu, T., Li, L., & Li, Q. (2018) · Depression and Anxiety · doi:10.1002/da.22811 · Cited by 81
Irritable bowel syndrome: Role of food in pathogenesis and management
Morcos, A. I., Dinan, T. G., & Quigley, E. M. M. (2009) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2009.00392.x · Cited by 85
Barbara, G., Zecchi, L., Barbaro, M. R., Cremon, C., Bellacosa, L., Marcellini, M. M., GIORGIO, R. D., Corinaldesi, R., & Stanghellini, V. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318264e918 · Cited by 82
Layer, P., Andresen, V., Allescher, H. ‐., Bischoff, S. C., Claßen, M., Elsenbruch, S., Freitag, M., Frieling, T., Gebhard, M., Goebel‐Stengel, M., et al. (2021) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1591-4794 · Cited by 81
Wang, J., Bai, X., Peng, C., Yu, Z., Li, B., Zhang, W., Sun, Z., & Zhang, H. (2020) · Journal of Dairy Science · doi:10.3168/jds.2020-18639 · Cited by 80
Probiotics in the Management of Functional Bowel Disorders
Quigley, E. M. M. (2012) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2012.08.005 · Cited by 77
Pharmacological management of constipation
Emmanuel, A. V., Tack, J. F., Quigley, E. M. M., & Talley, N. J. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01403.x · Cited by 75
Camilleri, M., & Chang, L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.005 · Cited by 74
Mazurak, N., Broelz, E. K., Storr, M., & Enck, P. (2015) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm15071 · Cited by 75
Probiotic effects on intestinal fermentation patterns in patients with irritable bowel syndrome
Barrett, J. S., Canale, K. E., Gearry, R. B., Irving, P. M., & Gibson, P. R. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.5020 · Cited by 72
Probiotics, prebiotics and the gastrointestinal tract in health and disease
Vitetta, L., Briskey, D. R., Alford, H., Hall, S., & Coulson, S. (2014) · Inflammopharmacology · doi:10.1007/s10787-014-0201-4 · Cited by 72
Schmulson, M., & Chang, L. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04637.x · Cited by 70
Probiotic fermented milks: Present and future
Sánchez, B., Reyes‐Gavilán, C. G. D. L., Margollés, A., & Gueimonde, M. (2009) · International Journal of Dairy Technology · doi:10.1111/j.1471-0307.2009.00528.x · Cited by 71
Metadata
- Authors
- GUYONNET, D., CHASSANY, O., DUCROTTE, P., PICARD, C., MOURET, M., MERCIER, C. ‐., & MATUCHANSKY, C.
- Affiliations
- Danone (France) (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre Hospitalier Universitaire de Rouen (FR)
- Université Paris Diderot (FR)
- Corresponding author
- GUYONNET, D.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2007-05-04
- Volume
- 26
- Issue
- 3
- Pages
- 475-486
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2149809125
- Cited by
- 365
- References
- 68
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 15 · 2023: 11 · 2022: 10 · 2021: 15 · 2020: 14 · 2019: 19 · 2018: 25 · 2017: 18 · 2016: 23 · 2015: 14 · 2014: 18 · 2013: 27 · 2012: 27
- FWCI
- 17.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Alimentary Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- HAL (Le Centre pour la Communication Scientifique Directe) (submittedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- irritable bowel syndrome, irritable bowel syndrome with constipation, probiotics, fermented milk, yogurt, health-related quality of life, bloating, stool frequency
- MeSH terms
- Adolescent, Adult, Aged, Bifidobacterium, Double-Blind Method, Female, Humans, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
